Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort
CONCLUSION: Pediatric patients with FH followed up in specialist lipid clinics in France receive late treatment, undertreatment, or suboptimal treatment and half of them do not reach the therapeutic LDL-C goal. Finding a more efficient framework for linking scientific evidence to clinical practice is needed.PMID:38538465 | DOI:10.1016/j.arcped.2024.01.004
Source: Archives de Pediatrie - Category: Pediatrics Authors: Noel Peretti Alexandre Vimont Emmanuel Mas Julie Lemale Rachel Reynaud Patrick Tounian Pierre Poinsot Liora Restier Fran çois Paillard Alain Pradignac Yann Pucheu Jean-Pierre Rab ès Eric Bruckert Antonio Gallo Sophie B éliard Source Type: research
More News: Cardiology | Cardiovascular | Children | Cholesterol | Databases & Libraries | France Health | Genetics | Heart | Pediatrics | Statin Therapy | Study | Vytorin | Zetia